anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Combined treatment group:mononuclear cells were obtained aseptically with blood cell separator composition spheresis 1 day before SOX program chemotherapy, cultured DC-CIK cells. SOX program was acted on Day 2. Cells were cultured 14d,2 times back to the patient.A 21d was a cycle, then evaluated the therapeutic effect after two cycles.
PURPOSE:To provide a functional bathing agent giving fragrance of bitter orange when thrown in bath water, capable of giving dampishness to bather skin, also of giving relaxed feeling and sound sleeping effect after bathing. CONSTITUTION:The objective bathing agent contains, as the essential ingredients, (A) xylooligosaccharide and/or oolong tea extract and (B) bitter orange essential oil. The amounts of the ingredients A and B to be formulated are such that, when the bathing agent is dissolved in bath water, their concentration come to >=0.001wt.% and >=0.0001wt.%. The component A has humectant effect esp., a combination of the xylooligosaccharide with the oolong tea extract has its synergistic effect. The component B is highly fragrant, being pale yellow, and its fragrance is sustainable, thus obtaining the objective bathing agent having the above-mentioned advantages. This bathing agent can further be formulated with other functional ingredient(s) such as octacosanol or other ingredient(s) used as raw materials) for conventional bathing agents at pref. 0-2000 pts.wt. based on 100 pts.wt. of the above essential ingredients.
After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique. children will receive intrathecal morphine 5 μg/kg in 2 ml volume normal saline.
Triple-negative breast cancer (TNBC) is a highly aggressive and invasive form of breast cancer (BC) with a high mortality rate and a lack of effective targeted drugs. Family with sequence similarity 83 member H (FAM83H) is critically implicated in tumorigenesis. However, the potential role of FAM83H in TNBC remains elusive. Here, we discovered that FAM83H exhibited high expression in tumor tissues of patients with TNBC and was associated with TNM stage. Gain- or loss-of-function experiments were conducted to explore the biological role of FAM83H in TNBC. Subsequently, functional enrichment analysis confirmed that FAM83H overexpression promoted TNBC cell proliferation, invasion, migration and epithelial-mesenchymal transition (EMT), accompanied by upregulation of cyclin E, cyclin D, Vimentin, N-cadherin and Slug. As observed, FAM83H knockdown showed anti-cancer effects, such as fostering apoptosis and inhibiting tumorigenicity and metastasis of TNBC cells. Mechanistically, FAM83H activated the NF-κB signaling pathway. Moreover, a dual-luciferase reporter assay demonstrated that GLIS family zinc finger 3 (GLIS3) bound to the promoter of FAM83H and enhanced its transcription. Notably, overexpression of GLIS3 significantly stimulated TNBC cell proliferation and invasion, and all of this was reversed by rescue experiments involving the knockdown of FAM83H. Overall, FAM83H exacerbates tumor progression, and in-depth understanding of FAM83H as a therapeutic target for TNBC will provide clinical translational potential for intervention therapy.
Both the subject matter experts and older adult participants will participate in individual structured interviews for each activity category, 1.5 - 2 hours in length. This qualitative data will provide rich contextualized information regarding the specific needs of older adults for access to services, financial health management, and Medicare.gov services utilization. This data will be used to identify current barriers and facilitators to successful healthcare management that could be targeted by technology solutions and/obtain details of the challenges that are common in each activity category.
The present invention relates to an externally applied Chinese medicine preparation for dispelling wind and removing dampness and a method for preparing the externally applied Chinese medicine preparation. The externally applied Chinese medicine preparation is prepared by that banfenghe, longpeduncle kadsura stems, uncaria, herbs of glabrous sarcandra, epimedium herbs, etc. are pulverized into coarse powders, percolation is carried out by adopting a conventional percolation method with ethanol as solvent, and then, percolate is collected according to the prior art to be made into the Chinese medicine preparation. Compared with the prior art, the present invention is suitable for treating series cold, bodily pain, deadlimb, hemiplegia, pain in legs and waists, etc. which are caused by cold and dampness. In the medicinal theory of miao nationality, because of natural environment influence and climatic variation, toxins of cold and dampness invade human bodies to cause qi stop, blockage of blood vessels, qi and blood stagnation and muscle condensation because of cultivation loss, and then, the disease symptoms of serious cold, bodily pain, deadlimb, hemiplegia, pain in waists and legs, etc. appear.
Bullous pemphigoid (BP) is a common autoimmune bullous disease affecting mainly the elderly, with rising incidence due to increased life expectancy. This disease is characterized by tense bullous lesions on normal or erythematous skin, accompanied by pruritus. BP pathogenesis involves autoantibodies against hemidesmosomal proteins BP180 and BP230, leading to detachment at the dermo-epidermal junction as well as blister formation. BP is associated with coexisting comorbidities and drug exposure, and its management often requires high doses or chronic use of systemic glucocorticoids, posing risks of adverse effects. This review focuses on novel treatment options for BP, exploring therapies targeting different immune pathways. Rituximab, a CD20 monoclonal antibody, depletes B-lymphocytes and has shown efficacy in severe cases. Dupilumab, targeting interleukin (IL)-4 receptor α and thus blocking IL-4 and IL-13, downregulates type 2 helper (Th2) responses and has demonstrated promising results. Targeting eosinophil-related molecules using bertilimumab and AKST4290 has yielded positive results in clinical trials. Omalizumab, an immunoglobulin (Ig) E antibody, can reduce disease severity and allows corticosteroid tapering in a number of cases. Complement inhibitors such as nomacopan and avdoralimab are being investigated. IL-17 and IL-23 inhibitors such as secukinumab and tildrakizumab have shown potential in a limited number of case reports. Neonatal Fc receptor antagonists such as efgartigimod are under investigation. Additionally, topical therapies and Janus kinase inhibitors are being explored as potential treatments for BP. These novel therapies offer promising alternatives for managing BP, with potential to improve outcomes and reduce high cumulative doses of systemic corticosteroids and related toxicities. Further research, including controlled clinical trials, is needed to establish their efficacy, safety, and optimal dosing regimens for BP management.
The invention relates to a water-soluble dinuclear copper complex, and a preparation method and application thereof. The chemical formula is [CuL(NO3)2]2.CH3CH2OH,Wherein L is di(2-quinolylmethyl)benzylamine. The X single-crystal diffraction data indicates that the complex (1) belongs to a triclinic system, the space point group is P-1, and the cell parameters are disclosed in the specification; and alpha=77.437(10)degrees, beta=78.198(10) degrees, and gamma=85.112(9) degrees. The preparation method comprises the following steps: stirring ligands di(2-quinolylmethyl)benzylamine and copper nitrate with the same mole to react for 3-5 hours, filtering, and standing the filtrate to obtain a blue-green crystal product. The complex has high bonding action with CT-DNA (calf thymus-deoxyribonucleic acid), and the mode of action is partial intercalation. The complex can rupture the pBR322 plasmid DNA in an autoxidation cutting mode under the condition of not adding any oxidizing or reducing agent. Besides, the complex can initiate endogenous fluorescent quenching of BSA (bovine serum albumin) through static quenching. The preparation method is simple and reliable.
The present invention relates to compositions comprising the botanicals from the Family Ranunculaceae, Subclass: Dicotyledonae; Crassinucelli, Superorder: Ranunculales. Examples of these botanicals include but are not limited to;  Actaea, Anemone, Ranunculus , and  Nigella , or extracts thereof, which are useful in treating liver diseases, particularly those with viral etiology. More specifically, the compositions of the present invention are derived from various botanicals or medicinal plants. The compositions of the invention have demonstrated outstanding efficacy for treatment of patients with hepatic disorders. Compositions of the present invention have also exhibited immunomodulatory activities. The preferred compositions contain the botanical ingredients in concentrations of not less than 20% w/v. The treatment can be therapeutic or prophylactic and may be administered orally, parenterally, as suppository or via nasal mucosa. The treatment may be delivered in a single dose, multi-doses or via a slow release mechanism.
All patients that underwent congenital cardiac surgery from 2004 till 2010 and required PCA or NCA will be included. Data will be collected from the pain team database and charts review. Data will include; patient's age, weight, sex, procedure, pain scores and sedation score during the times of PCA and NCA use, side effects (respiratory depression, nausea, vomitting, pruritus, itching and other).In addition we will record the total days of PCA and NCA use. We will also look at the incidence of changes done in the PCA/NCA and drug itself.

Identifying the ideal drug and dose based on the patient's age and procedure will allow us to take better care of our patients. Our patient population is peculiar in the fact that a big percentage of our patients are extubated in the Operating Room. For this reason, sedation and analgesia play an important role for our continued success in taking care of them.
INTRODUCTION: We present two cases of vitreous hemorrhage after micropulse cyclophotocoagulation one of which had concurrent hyphema. To the best of our knowledge, these are the first cases of vitreous hemorrhage due to micropulse CPC in the United States.
CASE DESCRIPTION: The first case is an 82-year-old woman with bilateral severe primary open angle glaucoma. BCVA in the right eye was 20/25, and 10-2 Humphrey visual field showed severe peripheral defects. The patient underwent MPCPC of the right eye and at one week, a settled 2 mm hyphema and vitreous hemorrhage confirmed by B-scan were noted. At three months, the patient had a BCVA of 20/80 with an IOP of 12 and retina consultation deferred a PPV. The second case is of a patient with bilateral moderate stage POAG who underwent MPCPC in both eyes. His original VA was 20/200 bilaterally. At 2 weeks, RE VA was count fingers at one foot and LE was 20/150-1. At two months, a RE B scan revealed dense vitreous opacities. Retina consultation revealed vitreous hemorrhage but a PPV was deferred.
CONCLUSION: Clinicians should be aware of the risks of bleeding and the potential need for additional surgical interventions after MPCPC.
PURPOSE: A system and a method for diet management are provided to classify personal data of users by body type, and offer a customized solution according to diet objective, lifestyle analysis result, and state diagnosis data that are classified by the body type. CONSTITUTION: A diet management server receives person informative data of a user from an information input terminal through a data transmitting/receiving unit(S310). The diet management server generates body type classification data by classifying users by body types with received state diagnosis data, and transmits the generated body type classification data to a data DB though the data transmitting/receiving unit(S320). A lifestyle analysis unit of the diet management server generates result of lifestyle analysis according to received lifestyle data(S330). A solution generation unit of the diet management server generates a solution for each user using a solution data DB based on a diet objective of each user, the analysis result of lifestyle and state diagnosis data(S340). A customization service providing unit of the diet management server provides a customized solution which is changed in accordance with a current situation of the user by receiving the current situation of the user(S350). [Reference numerals] (510) Receive user's BMI and 3D body type analysis result from a state diagnosis DB; (520) Classify body fat degrees according to the user's BMI; (530) Classify body types according to the user's 3D body type analysis result; (540) Determine user's body type based on the body fat degree and body type classifications; (550) Generate body type classification data and store in a body type classification DB; (AA) Start; (BB) End
Acute lymphoblastic leukemia (ALL), a leading cause of childhood cancer, targets immune system B and T cells. While understanding its causes is crucial, predicting susceptibility holds immense power for early diagnosis and intervention. This study explored the potential of interleukin 10 (IL-10), a key immune regulator, as a predictive tool in Egyptian children. Investigating 100 ALL patients and 100 healthy controls, we analyzed the IL10 gene polymorphism (-1082 A/G) and serum levels. Strikingly, both the G allele and higher serum IL-10 levels were significantly associated with increased ALL risk (p < 0.05, OR > 1). Moreover, IL-10 emerged as a remarkably accurate predictor, boasting an AUC of 0.995, with a sensitivity of 97% and specificity of 96%. These findings unveil the potential of IL-10 as a powerful predictive tool for pediatric ALL in the studied Egyptian population. Identifying individuals with the GG/AG haplotype and elevated IL-10 levels could enable early intervention and potentially improve outcomes. While further validation in larger and more diverse populations is needed, this study paves the way for personalized risk assessment and potentially revolutionizes how we combat this childhood killer.
Serum cholesterol is transported by lipoproteins, such as VLDL, LDL, and HDL, which vary in their relationship to cardiovascular disease risk. LDL, for example, is proatherogenic, whereas HDL is cardio-protective. Palmitoleic acid (cis-C16:1 n-7), an omega-7 fatty acid with 16 carbons in length with a single double bound in the n-7 position, have been shown in mice and human to decrease proatherogenic lipoproteins, such as LDL, and reduce cardiovascular risk factors. This study will test the hypothesis that palmitoleate supplementation in humans will favorably alter the lipoprotein lipid profile in regard to cardiovascular disease risk. We will also assess other parameters related to lipoprotein composition and function, as well as other biomarkers related to coagulation and inflammation, which have previously been shown to be possibly affected by supplementation with omega-7 fatty acid. In addition, previous animal studies have indicated the palmitoleate induced satiety and suppressed bodyweight gain, possibly through enhancement of the release of satiety hormones. In this clinical trial, we, therefore will also examine the effect of concentrated palmitoleate on satiety.

This clinical research project is designed as a pilot, randomized, double-blinded, crossover study that will investigate the effect of concentrated oil enriched with palmitoleate on lipoprotein metabolism and satiety. Subjects will either receive control olive oil enriched in oleic acid, a longer-chain monounsaturated fatty acid (cis-C18:1 n-9), or a concentrate oil supplement produced from pollock fish (rich in palmitoleate) for approximately 8-10 weeks, with a wash out period of 8-10 weeks between the two arms of the study. The study consists of 4 outpatient visits when laboratory or research samples will be performed. A 7-day food diary, pill count, and red cell membrane fatty acid levels will be monitored to assess compliance. The effect of the supplement on satiety will be assessed at each visit.
This will be a prospective randomized study assessing the efficacy of stenting moderate SVG lesions with the taxus stent in the prevention of atherosclerosis progression of SVGs as evaluated by IVUS. Patients with previous coronary bypass surgery with SVG implantation undergoing coronary angiography by clinical indication will be screened. If the patient has a moderate lesion at any level of the SVGs it will be includable in the study. After inclusion, the patients will be randomized to either stenting the moderate SVG lesion with the taxus stent or standard medical treatment. The use of a filter wire during dilation will be strongly recommended. Following this procedure, all patients will have clinical controls at 1 month and at 6 months and an angiographic and IVUS control study at 1 year follow-up.
Following approval of the University of Minnesota Institutional Review Board, 33 consecutive adult patients (≥ 18 years of age) were observed from October 2013 to December 2014 who underwent either single or bilateral lung transplantation and received a continuous paravertebral block. The paravertebral catheters were placed within 1-2 day postoperatively in the intensive care unit. If the patient was too hemodynamically unstable or too critically ill to be placed in lateral decubitus position, the placement of the catheter was delayed or in some cases not performed (these patients were not included in study) They were placed via an in plane transverse technique. The ultrasound was placed on the patient's back at the T8-9 level with probe in transverse orientation. Then a 17-gauge tuohy needle was advanced lateral to medial in plane until beneath the transverse process upon which a test dose of 3-5 mL of 1.5% lidocaine with 1:200,000 epinephrine was injected to see adequate spread. The catheter was then fed 1 centimeter past the tip of the tuohy needle and needle was withdrawn. All catheters were confirmed to be in correct position with real time local anesthetic injection and secured with skin glue and occlusive dressing. Each was performed with the patient in the left lateral decubitus position for the right catheter and right lateral decubitus position for the left catheter. The paravertebral catheters remained in place for up to seven days postoperatively in unilateral lung transplants and up to ten days postoperatively in bilateral lung transplants. During that time an infusion of 0.2% ropivacaine was infused at a rate of 0.2-0.25 ml/kg/hour through an elastomeric pump (ON Q Halyard Health).

The outcome measured were minimal and maximum pain scores from the first 7 days post paravertebral catheter placement (rated on an 11-point numeric rating scale; 0=no pain, 10=worst pain imaginable). The acute pain Nurse Practitioners, bedside nurses, or acute pain anesthesiology residents collected the pain scores. Additional outcomes of interest included postsurgical opioid use through postsurgical day 7, and length of hospital stay. Patients were asked daily if they experienced nausea/vomiting, however, Nursing notes and physician progress notes were also evaluated if patients experienced any adverse events or nausea and vomiting. Demographics such as age and weight were recorded in addition to length of surgery and time spent in the hospital before discharge.
Evaluation will be conducted at three assessment time points including baseline assessment (following initial medical intervention), assessment at the time of discharge from the intensive care center (an average of 2 weeks), and discharge from the hospital (an average of 4 weeks). After recruiting in this study, participants all receive the intervention of e-MCIT.
The present invention discloses a kind of Chinese medicine composition for treating tumor. The Chinese medicine composition consists of alkaloid extracted from flavescent sophora root and oleanolic acid and other triterperic acid compound extracted from privet fruit in certain ratio. Of the Chinese medicine composition, the flavescent sophora root extract contains flavescent sophora alkaloid in 50-100 %, and the privet fruit extract has oleanolic acid content in triterperic acid compounds in 50-99.5 %. The components in the Chinese medicine composition can generate synergistic effect. The experiment on S180 sarcoma and Lewis lung cancer in animal's body and other pharacodynamic experiment show that the Chinese medicine composition has effect of reducing leucopenia and other tumor radiotherapy and chemotherapy toxic side effects. The Chinese medicine composition may be used by patient regularly.
Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.

Use aseptic technique for single or multiple entry and withdrawal from all containers. When diluting or dissolving drugs, mix thoroughly and use promptly.

Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.

Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.
Age-related macular degeneration (AMD) is a degenerative ocular disease primarily affecting central vision in the elderly. Its pathogenesis is complex, involving cellular senescence and immune homeostasis dysregulation. This review investigates the interaction between these two critical biological processes in AMD pathogenesis and their impact on disease progression. Initially, cellular senescence is analyzed, with particular emphasis on retinal damage induced by senescent retinal pigment epithelial cells. Subsequently, the occurrence of immune homeostasis dysregulation within the retina and its mechanistic role in AMD areis explored. Furthermore, the paper also discusses in detail the interplay between cellular senescence and immune responses, forming a vicious cycle that exacerbates retinal damage and may influence treatment outcomes. In summary, a deeper understanding of the interrelation between cellular senescence and immune dysregulation is vital for the developing innovative therapeutic strategies for AMD.
The present disclosure relates to novel processes for the preparation of compounds of Formula I. Some of these compounds are useful as stimulators of soluble guanylate cyclase (sGC). Others are useful intermediates towards the preparation of said stimulators. These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula I in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.
Patients will be started on antibiotics for treatment of pneumonia per usual care by their medical provider team. The research team will monitor enrolled patients daily for markers of their clinical status (caregiver assessment of respiratory status, supplemental oxygen/respiratory support, presence of fever). Once the patient has been "clinically stable" x48 hours, antibiotics will be discontinued.